Brand names: Angiotensin Ii
Vasoconstrictor
Route: Intravenous
Contraindications
4 CONTRAINDICATIONS None. None (4.1)
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary The published data on angiotensin II use in pregnant women are not sufficient to determine a drug-associated risk of adverse developmental outcomes. Animal reproduction studies have not been conducted with Angiotensin II. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Septic or other distributive shock is a medical emergency that can be fatal if left untreated. Delaying treatment in pregnant women with hypotension associated with septic or other distributive shock is likely to increase the risk of maternal and fetal morbidity and mortality.
73 interactions on record
Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor serum potassium concentrations.
Source: NLP:potassium phosphate, monobasic potassium phosphate, dibasic
Concomitant use with ARBs is contraindicated in diabetic patients and associated with increased risk of hypotension, hyperkalemia, and acute renal failure in others.
Source: NLP:aliskiren hemifumarate
Risk of hyperkalemia may be increased when amiloride HCl is administered concomitantly. Use with caution and frequent monitoring of serum potassium.
Source: NLP:amiloride hydrochloride and hydrochlorothiazide
Dual blockade of RAS with valsartan and other ARBs is associated with increased risks of hypotension, hyperkalemia, and changes in renal function including acute renal failure.
Source: NLP:amlodipine and valsartan
Use to control hypertension has been reported to induce anemia and severe leukopenia in patients on azathioprine.
Source: NLP:azathioprine
Dual RAS blockade with other angiotensin receptor blockers increases risks of hypotension, hyperkalemia, and acute renal failure. Avoid combined use.
Source: NLP:azilsartan kamedoxomil and chlorthalidone
Dual RAS blockade associated with increased risks of hypotension, hyperkalemia, and acute renal failure. Avoid combined use.
Source: NLP:benazepril hydrochloride
Dual RAS blockade associated with increased risks of hyperkalemia, hypertension, and acute renal failure. Avoid combined use.
Source: NLP:benazepril hydrochloride and hydrochlorothiazide
Dual blockade of RAS associated with increased risks of hypotension, hyperkalemia, and changes in renal function including acute renal failure compared to monotherapy.
Source: NLP:captopril
May diminish antihypertensive effect; in elderly, volume depleted, or renally impaired patients may result in deterioration of renal function.
Source: NLP:celecoxib
May diminish antihypertensive effect and result in renal function deterioration in vulnerable patients.
Source: NLP:diclofenac
May result in deterioration of renal function including possible acute renal failure in elderly, volume-depleted, or renally impaired patients. NSAIDs may diminish antihypertensive effect.
Source: NLP:diclofenac sodium
Dual blockade of RAS increases risk of hypotension, hyperkalemia, and acute renal failure compared to monotherapy.
Source: NLP:enalapril
Dual blockade of RAS associated with increased risks of hypotension, hyperkalemia, and changes in renal function including acute renal failure.
Source: NLP:enalapril maleate
Dual blockade of RAS associated with increased risks of hypotension, hyperkalemia, and acute renal failure compared to monotherapy.
Source: NLP:enalapril maleate and hydrochlorothiazide
Combination increases risk of hyperkalemia. Monitor serum potassium and renal function closely, especially in elderly or those with impaired renal function.
Source: NLP:eplerenone
Dual blockade of RAS is associated with increased risks of hypotension, hyperkalemia, and changes in renal function.
Source: NLP:fosinopirl sodium
May lead to severe hypotension and deterioration in renal function, including renal failure.
Source: NLP:furosemide
May lead to severe hypotension and deterioration in renal function, including renal failure. Monitor blood pressure and renal function; adjust dosage if needed.
Source: NLP:furosemide injection 80 mg/ 10 ml
Dual blockade of the RAS associated with increased risks of hypotension, hyperkalemia, and changes in renal function including acute renal failure. Avoid combined use.
Source: NLP:irbesartan
Dual RAS blockade increases risk of hypotension, hyperkalemia, and acute renal failure. Combined use should generally be avoided.
Source: NLP:irbesartan and hydrochlorothiazide
Concomitant use may increase the risk for anaphylactic-type reactions to iron dextran product.
Source: NLP:iron dextran
Dual blockade of RAS is associated with increased risks of hypotension, hyperkalemia, and changes in renal function including acute renal failure.
Source: NLP:lisinopril
Dual blockade of the RAS with angiotensin receptor blockers and lisinopril is associated with increased risk of hypotension, hyperkalemia, and changes in renal function including acute renal failure.
Source: NLP:lisinopril and hydrochlorothiazide
Concomitant use increases steady-state serum lithium concentrations.
Source: NLP:lithium
Concomitant use increases steady-state serum lithium concentrations, requiring frequent monitoring and dosage adjustment.
Source: NLP:lithium carbonate
Dual blockade of the renin-angiotensin system is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function including acute renal failure.
Source: NLP:losartan potassium and hydrochlorothiazide
Dual RAS blockade is associated with increased risks of hypotension, hyperkalemia, and changes in renal function including acute renal failure compared to monotherapy.
Source: NLP:moexipril hydrochloride
Agonistic effects increase phenylephrine blood pressure effect.
Source: NLP:phenylephrine hydrochloride
Concurrent use increases risk of severe and potentially fatal hyperkalemia, particularly in presence of other hyperkalemia risk factors.
Source: NLP:potassium chloride
Increases risk of severe and potentially fatal hyperkalemia, particularly in presence of other risk factors. Avoid use if possible.
Source: NLP:sodium chloride and potassium chloride
RAAS inhibitors that produce potassium retention; monitor for hyperkalemia with concomitant use.
Source: NLP:potassium chloride for oral solution
Concurrent use increases risk of severe and potentially fatal hyperkalemia, particularly with other hyperkalemia risk factors.
Source: NLP:potassium chloride and dextrose monohydrate
Produce potassium retention by inhibiting aldosterone production; closely monitor potassium levels.
Source: NLP:potassium citrate
Concurrent use may result in hyperkalemia and cardiac arrhythmias or cardiac arrest.
Source: NLP:potassium iodide
Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor serum potassium concentrations.
Source: NLP:potassium phosphates
Concomitant use may enhance the pressor response and increase the risk of hypertension.
Source: NLP:promethazine, phenylephrine, codeine
Avoid concomitant use as sacubitril and valsartan contains valsartan, an angiotensin II receptor blocker.
Source: NLP:sacubitril and valsartan
Concomitant use increases risk of severe and potentially fatal hyperkalemia, especially with other hyperkalemia risk factors. Avoid use; if unavoidable, closely monitor serum potassium.
Source: NLP:sodium chloride, potassium chloride, and calcium chloride
Angiotensin II receptor antagonists increase hyperkalemia risk; avoid use due to potassium content or monitor serum potassium concentrations.
Source: NLP:sodium chloride, sodium gluconate, sodium acetate, potassium chloride and magnesium chloride
Avoid concomitant use due to increased risk of severe and potentially fatal hyperkalemia. If unavoidable, closely monitor serum potassium concentrations.
Source: NLP:dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride
ARBs can increase serum potassium; concomitant use with spironolactone may lead to severe hyperkalemia. Check potassium levels when therapy is altered.
Source: NLP:spironolactone
Concomitant administration may lead to severe hyperkalemia.
Source: NLP:spironolactone and hydrochlorothiazide
Three cases of hyperkalemia in elderly patients reported after concomitant intake of sulfamethoxazole and trimethoprim and ACE inhibitors.
Source: NLP:sulfamethoxazole and trimethoprim
NSAIDs may diminish antihypertensive effect and cause further deterioration of renal function, including possible acute renal failure in patients with compromised renal function.
Source: NLP:sulindac
Increased risk of hypotension and renal impairment when used concomitantly with torsemide.
Source: NLP:torsemide
Dual blockade of RAS associated with increased risks of hypotension, hyperkalemia, and acute renal failure compared to monotherapy.
Source: NLP:trandolapril
Potassium-sparing diuretics with ACE inhibitors increase risk of hyperkalemia. Use with caution.
Source: NLP:triamterene
Greatly increased risk of hyperkalemia when potassium-sparing agents are used with ACE inhibitors. Serum potassium should be monitored frequently.
Source: NLP:triamterene and hydrochlorothiazide
Concomitant angiotensin-converting enzyme inhibitors may increase the risk of angioedema, particularly in patients with acute ischemic stroke.
Source: NLP:alteplase
Risk of hyperkalemia may be increased when used concomitantly with amiloride HCl. Requires caution and frequent monitoring of serum potassium.
Source: NLP:amiloride hydrochloride
When administered concomitantly, patients should be adequately hydrated and renal function assessed at baseline.
Source: NLP:diclofenac sodium, methyl salicylate
NSAIDs may diminish antihypertensive effect; in elderly, volume-depleted, or renally impaired patients, may cause renal function deterioration including acute renal failure.
Source: NLP:diclofenac sodium and misoprostol
May diminish antihypertensive effect; in elderly, volume-depleted, or renal impairment patients may result in deterioration of renal function.
Source: NLP:diclofenac sodium topical
NSAIDs may diminish antihypertensive effect and can cause renal impairment in elderly, volume-depleted, or renally impaired patients.
Source: NLP:diclofenac sodium, kinesiology tape
NSAIDs may diminish the antihypertensive effect of angiotensin II antagonists. Co-administration may result in further deterioration of renal function, including possible acute renal failure in patients with compromised renal function.
Source: NLP:diflunisal
May impair digoxin excretion by declining GFR or tubular secretion. Monitor renal function and digoxin levels.
Source: NLP:digoxin
May increase the glucose-lowering effect of glipizide, increasing susceptibility to hypoglycemia. Monitor closely.
Source: NLP:glipizide
May diminish antihypertensive effect and result in deterioration of renal function, including acute renal failure, in elderly, volume-depleted, or renal-impaired patients.
Source: NLP:indomethacin
May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.
Source: NLP:insulin aspart
May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.
Source: NLP:insulin aspart-szjj
May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Source: NLP:insulin degludec
May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Source: NLP:insulin glargine
May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.
Source: NLP:insulin glulisine
May increase risk of hypoglycemia; dose adjustment and increased glucose monitoring may be required.
Source: NLP:insulin human
May increase risk of hypoglycemia. Dose reductions and increased glucose monitoring may be required.
Source: NLP:insulin lispro-aabc
Concomitant use increases steady-state serum lithium concentrations. Recommend frequent monitoring and dosage adjustment.
Source: NLP:lithium citrate
Antihypertensives; small reductions in blood pressure occur following coadministration with tadalafil.
Source: NLP:macitentan and tadalafil
Concomitant use with meloxicam may diminish antihypertensive effect. In elderly, volume-depleted, or renally impaired patients, may result in deterioration of renal function. Monitor blood pressure and renal function.
Source: NLP:meloxicam
NSAIDs may diminish the antihypertensive effect of angiotensin receptor blockers.
Source: NLP:naproxen
Avoid use due to potassium content increasing risk of hyperkalemia. If unavoidable, monitor serum potassium concentrations.
Source: NLP:sodium lactate, potassium chloride, magnesium chloride, monobasic potassium phosphate, sodium chloride and dextrose monohydrate
Small reductions in blood pressure occurred following coadministration of tadalafil compared with placebo.
Source: NLP:tadalafil
Concomitant use increases hyperkalemia risk by approximately 1-2%. Serum potassium levels should be monitored.
Source: NLP:tolvaptan